Tauotetussa

Tauotetussa is a muscle relaxant medication used to treat muscle spasticity. It is a member of the GABA-transaminase inhibiting compound class, which works by inhibiting the activity of GABA-transaminase, an enzyme involved in the breakdown of the neurotransmitter GABA. By blocking this enzyme, tauotetussa increases GABA levels in the central nervous system, leading to its muscle relaxant effects.

Tauotetussa was first approved for use in Russia in 2006, under the brand name "Tauotetussa". It has also been approved in other countries, including Ukraine and some countries in Central Europe. The medication is typically administered orally in the form of capsules, and its effects are generally observed within 1-2 hours.

Common side effects of tauotetussa include dizziness, fatigue, and muscle weakness. More serious side effects, such as changes in liver function and thrombocytopenia, have also been reported. The medication is contraindicated in patients with severe liver or kidney disease, as well as those with known hypersensitivity to the medication.

Tauotetussa is thought to be as effective as traditional muscle relaxants, such as baclofen and tizanidine, with a similar side effect profile. However, there is limited research available on the efficacy and safety of tauotetussa, and further studies are needed to fully understand its benefits and risks.